1. Home
  2. ALGN vs EXEL Comparison

ALGN vs EXEL Comparison

Compare ALGN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALGN
  • EXEL
  • Stock Information
  • Founded
  • ALGN 1997
  • EXEL 1994
  • Country
  • ALGN United States
  • EXEL United States
  • Employees
  • ALGN N/A
  • EXEL N/A
  • Industry
  • ALGN Industrial Specialties
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ALGN Health Care
  • EXEL Health Care
  • Exchange
  • ALGN Nasdaq
  • EXEL Nasdaq
  • Market Cap
  • ALGN 9.9B
  • EXEL 10.4B
  • IPO Year
  • ALGN N/A
  • EXEL 2000
  • Fundamental
  • Price
  • ALGN $138.43
  • EXEL $38.94
  • Analyst Decision
  • ALGN Buy
  • EXEL Buy
  • Analyst Count
  • ALGN 13
  • EXEL 22
  • Target Price
  • ALGN $189.33
  • EXEL $44.10
  • AVG Volume (30 Days)
  • ALGN 1.2M
  • EXEL 2.9M
  • Earning Date
  • ALGN 10-29-2025
  • EXEL 11-04-2025
  • Dividend Yield
  • ALGN N/A
  • EXEL N/A
  • EPS Growth
  • ALGN N/A
  • EXEL 81.76
  • EPS
  • ALGN 5.16
  • EXEL 2.08
  • Revenue
  • ALGN $3,982,622,000.00
  • EXEL $2,230,005,000.00
  • Revenue This Year
  • ALGN $2.08
  • EXEL $9.14
  • Revenue Next Year
  • ALGN $3.28
  • EXEL $12.59
  • P/E Ratio
  • ALGN $25.55
  • EXEL $18.99
  • Revenue Growth
  • ALGN 0.56
  • EXEL 10.73
  • 52 Week Low
  • ALGN $122.00
  • EXEL $28.30
  • 52 Week High
  • ALGN $246.19
  • EXEL $49.62
  • Technical
  • Relative Strength Index (RSI)
  • ALGN 66.66
  • EXEL 53.00
  • Support Level
  • ALGN $130.73
  • EXEL $33.76
  • Resistance Level
  • ALGN $138.50
  • EXEL $40.63
  • Average True Range (ATR)
  • ALGN 3.89
  • EXEL 1.26
  • MACD
  • ALGN 1.22
  • EXEL 0.21
  • Stochastic Oscillator
  • ALGN 77.28
  • EXEL 83.62

About ALGN Align Technology Inc.

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Share on Social Networks: